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Abstract: The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
disease (COVID-19) has posed a serious threat to global health. As no specific therapeutics are yet 
available to control disease evolution, more in-depth understanding of the pathogenic mechanisms 
induced by SARS-CoV-2 will help to characterize new targets for the management of COVID-19. 
The present study identified a specific set of biological pathways altered in primary human lung 
epithelium upon SARS-CoV-2 infection, and a comparison with SARS-CoV from the 2003 pandemic 
was studied. The transcriptomic profiles were also exploited as possible novel therapeutic targets, 
and anti-signature perturbation analysis predicted potential drugs to control disease progression. 
Among them, Mitogen-activated protein kinase kinase (MEK), serine-threonine kinase (AKT), 
mammalian target of rapamycin (mTOR) and I kappa B Kinase (IKK) inhibitors emerged as 
candidate drugs. Finally, sex-specific differences that may underlie the higher COVID-19 mortality 
in men are proposed. 
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1. Introduction 
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a member of the 
Coronaviridae family, isolated at the end of 2019. It was on December the 31st, 2019, that the Chinese 
authorities for the first time reported to the World Health Organization (WHO) a series of pneumonia 
cases of unknown aetiology in Wuhan City, Hubei province, China [1], and it was on January the 9th, 
2020, that the Chinese Centre for Disease Prevention and Control declared that a novel coronavirus 
(initially named 2019-nCoV) was the causative agent [1]. The infection spreads rapidly in the 
population, mainly through respiratory droplets and close contact, with an  incubation period 
 ranging from 2 to 14 days [2]. The rapid propagation of the disease led the WHO to declare the state 
of “public health emergency of international concern” on January the 30th, 2020, and on March the 
11th, 2020, the WHO declared the Pandemic [3]. As of 09/04/2020, more than 1.4 million infected and 
almost 90 thousand of deaths have been reported (https://www.who.int/emergencies/diseases/novel-
coronavirus-2019/situation-reports/). However, the number of the infected are probably under-
estimated, since  the majority of cases are asymptomatic or show mild symptoms, such as dry cough, 
sore throat, and fever [4]. Even if there are many similarities with other coronaviruses, its high 
diffusion over the population in combination with the possibility to develop various fatal 
complications, including organ failure, septic shock, pulmonary edema, severe pneumonia, and 
Acute Respiratory Distress Syndrome (ARDS), make this virus a major problem for the public health 
[5]. It has been shown that males are more susceptible to COVID-19, reporting a prevalence between 
55% and 68% [6] and increased clinical severity and mortality [7]. However, the reason behind this 
epidemiological difference is still not clear. In the last two months, due to the state of emergency, the 
scientific community has prioritized the epidemiological studies on COVID-19 infection with 
consequential emerging of limited information regarding the molecular basis of the disease. In this 
paper, we have studied the transcriptomic profile of primary human lung epithelium infected by 
SARS-CoV-2, focusing on the most relevant pathways modulated during the infection and correlated 
their role to sex genes, providing a molecular hypothesis of the gender-differences observed from the 
clinical data. Then, we have performed a computational analysis to find new drugs candidates, based 
on their ability to modulate oppositely the transcriptional profiles.   
 
2. Materials and Methods  
2.1. Dataset selection  
The NCBI Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/) was 
manually searched using the MeSH term (Medical Subject Headings) “SARS-CoV-2”, “COVID-19” 
and “SARS”. The datasets were selected if they met the following criteria: (a) whole-genome 
transcriptomic profiling; (b) species of origin “Homo sapiens”; and (c) were not generated on cancer 
cell lines. Finally, two datasets were included: GSE147507 [8]  and GSE47963 [9]. Briefly, the 
GSE147507 dataset included 3 independent biological replicates of primary human lung epithelium 
that were mock treated or infected with SARS-CoV-2 (USA-WA1/2020) at a MOI (Multiplicity Of 
Infection) of 2, for 24h. For the generation of this dataset, mRNA enriched libraries were prepared 
from total RNA using tTruSeq Stranded mRNA LP. cDNA libraries were sequenced using an 
Illumina NextSeq 500 platform. Raw sequencing reads were then aligned to the human genome 
(hg19) using the RNA-Seq Alignment App on Basespace (Illumina, CA, USA). The GSE47963 dataset 
included data from human airway epithelium cultures infected with SARS-CoV at a MOI of 2 or mock 
controls, for increasing time points (24-96h). Transcriptomic profiling was performed using the 
Agilent 4×44K human HG arrays. The submitter-supplied pre-preprocessed and normalized gene 
expression matrix was used for the analysis. 
 
 
2.2. Network analysis 
 
The GeneMania database [10] was used to construct the network of the Differentially Expressed 
Genes (DEGs). Interaction data were defined as physical interaction, co-expression, predicted, co-
localization, pathway, genetic interactions, and shared protein domains. The Cytoscape software [11] 
 was used for the visualization of the network, with color-coded nodes based on the fold-change, and 
to perform network analysis, using the NetworkAnalyzer utility. Topological analysis was performed 
considering the network as undirected (i.e., containing only undirected edges). Centrality of each 
node in the network was ranked based on degree centrality, that corresponds to the number of edges 
linked to each given node. Closeness centrality and Betweeness centrality were also computed. 
Closeness centrality is a measure of how fast information spreads from a given node to other nodes 
in the network, while Betweenness centrality quantifies the number of times a node acts as a bridge 
along the shortest path between two other nodes. MCODE (Molecular Complex Detection) was used 
for module analysis of the network in Cytoscape [12]. The criteria of MCODE were as follows: degree 
cutoff = 2, node cutoff = 0.2, maximum depth = 100, and k-score = 2. 
 
2.3. Enrichment analysis 
Functional enrichment analysis was conducted using the web-based utility, Metascape [13]. 
Metascape analysis is based on publicly available databases, e.g. Gene Ontology, KEGG, and 
MSigDB. Metascape automatically aggregates enriched terms into non-redundant groups, by 
calculating the pairwise similarity between any two terms [13]. Metascape uses the hypergeometric 
test and Benjamini–Hochberg p value correction algorithm to identify statistically significant 
enriched ontology terms.  
For the identification of transcription factors and the comparative analysis of SARS-CoV2 
induced-phenotype with the normal lung tissue, the Enrichr (http://amp.pharm.mssm.edu/Enrichr) 
web-based utility was used [14]. To this aim, the Encode_CHEA_Consensus_TFs and the GTEx 
libraries were considered. EnrichR computes the p value using the Fisher’s exact test. The adjusted 
p-value is calculated using the Benjamini-Hochberg method for correction for multiple hypotheses 
testing. The z-score is computed using a modification to the Fisher exact test and assesses the 
deviation from the expected rank. Finally, the Combined Score is calculated by p value and the z-
score (Combined Score = ln(p value) × z-score).  
2.4. Drug Prediction Analysis 
The L1000FDW web-based utility [15] was used to identify potential drugs for the treatment of 
COVID-19. L1000FWD computes the similarity between a gene expression profile and the Library of 
Integrated Network-based Cellular Signatures (LINCS)-L1000 data, in order to prioritize drugs 
potentially able to reverse the input transcriptional feature [15]. The L1000 transcriptomic database 
belongs to the Library of Integrated Network-based Cellular Signatures (LINCS) project, a NIH 
Common Fund program, and includes the transcriptional profiles of ~50 human cell lines upon 
exposure to approximately 20,000 compounds, in a range of concentrations and time [15].  
 
2.5. Statistical Analysis 
For the differential expression analysis of the GSE147507 dataset, the VOOM (mean-variance 
modelling at the observational level) algorithm was used. The VOOM method estimates the mean-
variance relationship of the log-counts, generates a precision weight for each observation and enters 
these into the limma empirical Bayes analysis [16]. The analysis of the GSE47963 dataset was 
performed using the LIMMA function. The cloud-based application WebMeV (Multiple Experiment 
Viewer) was used for the statistical analyses [17]. Genes with an adjusted p value < 0.05 and a ǀfold 
changeǀ > 2 were identified as DEGs (Differentially Expressed Genes) and selected for further 
analysis.  
Linear regression and Spearman’s correlation were performed to compare the fold change of 
genes modulated upon SARS-CoV-2 infection and following SARS-CoV infection, at different time 
points.  
 Differences in the Combined Score for the enrichment of the lung tissue profile between women 
and men, stratified by age, was performed using the Mann-Whitney U test, followed by Benjamini–
Hochberg multiple test correction procedure. 
The GraphPad Prism (v. 8) software (San Diego, CA, USA) was used for the statistical analysis 
and the generation of the graphs. Unless otherwise stated, a p value<0.05 was considered for 
statistical significance. 
3. Results 
3.1. Network and enrichment analysis of SARS-CoV-2 infection 
In order to identify a specific gene signature characterizing SARS-CoV-2 infection, we first 
interrogated the GSE147507 dataset. We identified 129 DEGs, 94 upregulated and 35 downregulated 
(Figure 1A). MCODE analysis identified 7 main clusters of associated genes (Figure 1B; suppl. File 1). 
Gene term enrichment analysis for the upregulated genes identified several altered pathways upon 
SARS-CoV-2 infection, with the top three being: “cytokine-mediated signaling pathway”, “IL-17 
signaling pathway”, and “defense response to other organism” (Fig. 1C). No significant enriched 
term was instead found for the downregulated DEGs. Among the statistically significant enriched 
terms, intracellular pathways related to NFkB, toll-like receptors and MAPK were also found (Fig. 
1C). Accordingly, analysis of the transcription factors putatively involved in the regulation of the 
upregulated DEGs identified RELA (adj. p value=0.047), for its role to transcribe 9 out of the 94 DEGs, 
i.e. BST2, IL32, TNIP1, ICAM2, TNFAIP3, MMP9, BIRC3, RND1 and ICAM1 (Figure 1D). Interestingly, 
a number of DEGs were found to be modulated by sexual hormones, as ESR1 (Estrogen Receptor 1) 
was found to be involved in the regulation of 4 DEGs (C3 and EDN1, among the upregulated genes; 
and PDK4 and VTCN1, among the downregulated DEGs) and AR (Androgen Receptor) was found 
to regulate 6 DEGs (CCL20 and CXCL1, among the upregulated genes, and THBD, HEY2, BBOX1 and 
MYLK, among the downregulated genes) (Figure 1D and Suppl. File 1). Network analysis identified 
as the top hub genes, MX1, IL8 and IFITM1 (table 1). 
 
 
 
 
 
  
Figure 1. A) Gene network constructed using the Differentially Expressed Genes (DEGs) identified in 
the GSE147507 dataset. Nodes are color-coded based on the fold-change; B) MCODE clustering for 
the identification of neighborhoods where genes are densely connected; C) Gene Term enrichment 
using the upregulated DEGs identified in the GSE147507 dataset; D) Maps showing the potential 
transcription factors regulating the expression of the upregulated genes in the GSE147507 dataset 
 
 
Table 1. Network analysis with the top 50 genes ranked based on the degree of distribution 
Gene Degree 
Betweenness 
Centrality 
Closeness 
Centrality 
MX1 156 0.005556 0.4875 
IL8 149 0.023353 0.573529 
IFITM1 132 0.027499 0.52 
IFI44L 129 0.001489 0.45 
CXCL1 129 0.027552 0.573529 
CXCL2 119 0.02143 0.567961 
S100A8 118 0.026276 0.551887 
IRF7 117 0.00215 0.466135 
IFI27 116 0.022974 0.522321 
OAS1 116 0.004078 0.464286 
IL1B 116 0.026433 0.557143 
IL6 115 0.007298 0.531818 
TNFAIP3 112 0.029273 0.559809 
ICAM1 112 0.035752 0.579208 
XAF1 110 0.004523 0.483471 
MX2 110 0.007159 0.473684 
CXCL3 109 0.027718 0.554502 
IRF9 106 0.011689 0.46063 
A
B
C
D
0 10 20 30
PID INTEGRIN2 PATHWAY
modification of morphology or physiology of other organism
PID TOLL ENDOGENOUS PATHWAY
toll-like receptor signaling pathway
transepithelial transport
positive regulation of peptidyl-tyrosine phosphorylation
regulation of endopeptidase activity
regulation of smooth muscle cell proliferation
positive regulation of MAPK cascade
I-kappaB kinase/NF-kappaB signaling
myeloid leukocyte activation
Metal sequestration by antimicrobial proteins
cornification
positive regulation of cell migration
Interleukin-4 and Interleukin-13 signaling
positive regulation of response to external stimulus
NF-kappa B signaling pathway
defense response to other organism
IL-17 signaling pathway
cytokine-mediated signaling pathway
-Log(q-value)
 OAS2 104 0.010199 0.481481 
BST2 98 0.003963 0.483471 
IFI6 91 0.008014 0.485477 
S100A9 89 0.031773 0.541667 
BIRC3 89 0.028051 0.549296 
CCL20 80 0.027608 0.544186 
CXCL6 79 0.016894 0.534247 
OAS3 69 0.008639 0.46063 
S100A12 62 0.020722 0.524664 
PI3 61 0.035629 0.546729 
KRT6B 60 0.036157 0.524664 
TNFAIP2 59 0.007819 0.513158 
TNF 59 0.030233 0.52 
BCL2A1 58 0.007818 0.510917 
CXCL5 57 0.011576 0.517699 
S100A7 56 0.025749 0.513158 
MMP9 56 0.026879 0.534247 
SAA1 52 0.016882 0.524664 
HBEGF 49 0.020569 0.4875 
EPSTI1 48 0.000839 0.433333 
CSF3 47 0.00449 0.50431 
MAFF 42 0.019563 0.515419 
CFB 42 0.010391 0.5 
PDZK1IP1 40 0.018457 0.524664 
IL32 40 0.005467 0.483471 
LIF 40 0.006298 0.491597 
C3 39 0.013371 0.50431 
IL1A 35 0.008345 0.502146 
INHBA 34 0.022095 0.506494 
ICAM2 34 0.004401 0.483471 
STAT5A 33 0.010319 0.497872 
 
 
 
 
3.2. Comparison between SARS-COV-2 and SARS-CoV infection 
 
We next wanted to compare the gene signature induced by SARS-COV-2 and SARS-CoV 
infection. To this aim, we have interrogated the publicly available GSE47963 microarray dataset. We 
have first performed a correlation analysis on the modulation of the genes perturbed upon SARS-
CoV- infection and the corresponding genes in GSE47963. To account for the differences in the 
experimental setting, as well as the different technologies involved, we considered all the genes with 
a raw p value<0.05, irrespective of the fold-change. A total of 2871 genes were found to be modulated 
by SARS-CoV-2 and in common with the GSE47963 dataset. As shown in Figure 3A-B, a moderate 
but significant correlation is found between SARS-COV-2 and SARS-CoV infection at 24h, which 
increases when considering SARS-CoV infection at later time points. When a more stringent selection 
of the DEGs is applied (i.e., adj. p value<0.05 and ǀfold-changeǀ> 2), among the upregulated genes, 
only 1 gene is in common between SARS-CoV-2 and SARS-CoV infections at 24h (CXCL2), 6 genes 
are in common between SARS-CoV-2 infection and SARS-CoV infection at 48h; 25 and 22 genes are 
in common between SARS-CoV-2 and SARS-CoV at 72h and 96h, respectively (Figure 2C, suppl file 
2). Accordingly, similar pathways are enriched between SARS-CoV-2 and SARS-CoV infection for 
the 72h and 96h time points (Figure 2D). Among the downregulated genes, only 1 and 4 genes are in 
common between SARs-CoV-2-19 and SARS-CoV at 72h and 96h, respectively (Figure 2E, suppl file 
2). 
  
 
Figure 2. A) Scatter plot showing the correlation of gene expression between SARS-CoV-2 infection 
and SARS-CoV infection at different time points; B) Analysis of correlation of genes modulated upon 
SARS-CoV-2 and SARS-CoV infection, at different time points; C) Circos plot showing the 
overlapping between the genes significantly upregulated following SARS-CoV-2 infection and genes 
upregulated upon SARS-CoV infection at different time points. Purple lines link the same genes that 
are shared by the input lists. Blue lines link the different genes that fall in the same ontology term; D) 
Hierarchical clustering of the top most enriched terms by genes significantly upregulated upon 
infection. The heatmap is colored by the p values, and grey cells indicate the lack of significant 
enrichment; E) Circos plot showing overlapping between the genes significantly downregulated 
following SARS-CoV-2 infection and genes downregulated upon SAR-CoV infection at different time 
points. Purple lines link the same genes that are shared by the input lists. Blue lines link the different 
genes that fall in the same ontology term; F) Hierarchical clustering of the top most enriched terms by 
the downregulated genes upon infection. The heatmap is colored by the p values, and grey cells 
indicate the lack of significant enrichment;  
 
 
3.3. Drug prediction analysis 
Anti-signature perturbation analysis was performed using the DEGs identified for SARS-CoV-2 
infection (Figure 3A). In Table 2, we have enlisted the potential drugs identified by the L1000FWD 
analysis. Among them, the top three drugs are: BRD-K23875128, a Rho kinase inhibitor; SA-792728, 
a sphingosine kinase inhibitor; and sirolimus, an mTOR inhibitor. Figure 3B shows the relative 
percentage of the drugs based on their mode of action, which identifies the inhibitors of MEK, as the 
most represented drug category (Figure 3B).  
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Figure 3. A) L1000FDW visualization of drug-induced signature. Input genes are represented by the 
significantly upregulated and downregulated genes obtained from the analysis of the GSE147507 
dataset, Blue and red circles identify drugs with similar and anti-similar signatures. Dots are color-
coded based on the similarity score; B) Percentage of drug categories identified by the L1000FDW 
analysis 
 
 
Table 2. List of potential drugs for SARS-CoV-2 infection as identified by the L1000FWD analysis 
drug 
similarity 
score 
P 
value 
Q 
value 
Z score 
combined 
score 
mode of action 
BRD-K23875128 -0.2717 
3.53E-
23 
3.08E-
20 
1.82 -40.95 Rho kinase inhibitor 
SA-792728 -0.2391 
3.53E-
18 
1.11E-
15 
1.75 -30.61 sphingosine kinase inhibitor 
sirolimus -0.2391 
2.10E-
18 
7.19E-
16 
1.77 -31.33 MTOR inhibitor 
BRD-K44366801 -0.2283 
4.53E-
17 
1.17E-
14 
1.75 -28.62 Unknown 
TPCA-1 -0.2174 
5.15E-
16 
1.00E-
13 
1.8 -27.53 IKK inhibitor 
selumetinib -0.2174 
6.28E-
16 
1.16E-
13 
1.77 -26.83 MEK inhibitor 
ezetimibe -0.2174 
8.57E-
16 
1.53E-
13 
1.78 -26.83 
Niemann-Pick C1-like 1 protein 
antagonist|Cholesterol 
inhibitor 
desoximetasone -0.2174 
6.53E-
16 
1.20E-
13 
1.74 -26.47 Glucocorticoid receptor agonist 
BRD-K60070073 -0.2174 
1.44E-
16 
3.26E-
14 
1.69 -26.84 Unknown 
TPCA-1 -0.2174 
2.70E-
16 
5.72E-
14 
1.8 -27.95 IKK inhibitor 
BRD-K03601405 -0.2065 
9.63E-
16 
1.69E-
13 
1.79 -26.9 Unknown 
BRD-K88622704 -0.2065 
4.67E-
15 
7.02E-
13 
1.75 -25.08 Unknown 
AKT inhibitor
Antineoplastic
BCL inhibitor
Calmodulin antagonist
Cyclooxygenase inhibitor
Cytosolic phospholipase inhibitor
DNA synthesis inhibitor
EGFR inhibitor
FLT3 inhibitor
Glucocorticoid receptor agonist
HSP inhibitor
IKK inhibitor
MEK inhibitor
MTOR inhibitor
NPC1L1 antagonistRac GTPase inhibitorRho  kinase inhibitor
sphingosine kinase inhibitor
Ubiquitin specific protease inhibitor
Unknown
A B
 CT-200783 -0.2065 
1.73E-
15 
2.88E-
13 
1.82 -26.92 Unknown 
CAM-9-027-3 -0.2065 
4.81E-
16 
9.49E-
14 
1.89 -29.01 Unknown 
BRD-K25373946 -0.1957 
1.70E-
14 
2.28E-
12 
1.82 -25.07 Unknown 
piperlongumine -0.1957 
4.30E-
14 
5.35E-
12 
1.79 -23.92 Unknown 
BRD-K89687904 -0.1957 
3.43E-
14 
4.38E-
12 
1.79 -24.07 PKC inhibitor 
NSC-632839 -0.1957 
9.94E-
14 
1.11E-
11 
1.65 -21.47 
Ubiquitin specific protease 
inhibitor 
BRD-K03371390 -0.1957 
7.20E-
14 
8.33E-
12 
1.77 -23.28 Unknown 
BRD-K06765193 -0.1957 
3.18E-
14 
4.10E-
12 
1.73 -23.39 Unknown 
BRD-K32101742 -0.1957 
7.46E-
14 
8.56E-
12 
1.67 -21.95 Unknown 
WZ-4002 -0.1848 
1.25E-
12 
1.06E-
10 
1.64 -19.48 EGFR inhibitor 
U-0126 -0.1848 
1.10E-
12 
9.46E-
11 
1.69 -20.16 MEK inhibitor 
piperlongumine -0.1848 
2.30E-
13 
2.36E-
11 
1.84 -23.29 Unknown 
radicicol -0.1848 
3.85E-
13 
3.78E-
11 
1.75 -21.75 HSP inhibitor 
ABT-737 -0.1848 
3.40E-
12 
2.68E-
10 
1.73 -19.88 BCL inhibitor 
arachidonyl-trifluoro-methane -0.1848 
2.67E-
13 
2.68E-
11 
1.86 -23.43 
Cytosolic phospholipase 
inhibitor 
fluticasone -0.1848 
6.79E-
13 
6.35E-
11 
1.81 -22.07 Glucocorticoid receptor agonist 
BRD-K23875128 -0.1848 
1.53E-
12 
1.28E-
10 
1.78 -21.02 Rho kinase inhibitor 
tyrphostin-AG-1296 -0.1848 
4.14E-
13 
4.02E-
11 
1.87 -23.13 FLT3 inhibitor 
NVP-AUY922 -0.1739 
9.17E-
12 
6.31E-
10 
1.62 -17.92 HSP inhibitor 
TPCA-1 -0.1739 
1.67E-
11 
1.05E-
09 
1.8 -19.34 IKK inhibitor 
TPCA-1 -0.1739 
7.41E-
13 
6.81E-
11 
1.91 -23.18 IKK inhibitor 
ST-4070169 -0.1739 
8.32E-
12 
5.84E-
10 
1.73 -19.21 Unknown 
valdecoxib -0.1739 
1.67E-
11 
1.05E-
09 
1.78 -19.18 Cyclooxygenase inhibitor 
EMF-bca1-16 -0.1739 
9.17E-
12 
6.31E-
10 
1.68 -18.55 Unknown 
BIBU-1361 -0.1739 
7.06E-
12 
5.10E-
10 
1.82 -20.29 EGFR inhibitor 
MD-II-038 -0.1739 
1.11E-
11 
7.37E-
10 
1.74 -19.11 Unknown 
methoxsalen -0.1739 
1.48E-
11 
9.49E-
10 
1.79 -19.39 DNA synthesis inhibitor 
MK-2206 -0.1739 
8.88E-
12 
6.18E-
10 
1.8 -19.91 AKT inhibitor 
TPCA-1 -0.1739 
1.11E-
11 
7.37E-
10 
1.83 -20.02 IKK inhibitor 
phenethyl-isothiocyanate -0.1739 
8.06E-
12 
5.69E-
10 
1.82 -20.21 Antineoplastic 
BRD-A09984573 -0.1739 
8.32E-
12 
5.84E-
10 
1.71 -18.98 Unknown 
BRD-K12244279 -0.1739 
9.79E-
12 
6.66E-
10 
1.69 -18.64 MEK inhibitor 
PD-198306 -0.163 
8.94E-
11 
4.65E-
09 
1.7 -17.04 MEK inhibitor 
 BRD-K18726304 -0.163 
6.99E-
11 
3.76E-
09 
1.79 -18.18 Unknown 
calmidazolium -0.163 
4.07E-
11 
2.36E-
09 
1.73 -17.97 Calmodulin antagonist 
NSC-23766 -0.163 
7.44E-
11 
3.99E-
09 
1.79 -18.15 Rac GTPase inhibitor 
BRD-K66037923 -0.163 
1.58E-
10 
7.51E-
09 
1.75 -17.1 Unknown 
EMF-sumo1-11 -0.163 
2.87E-
10 
1.28E-
08 
1.65 -15.78 Unknown 
 
 
3.4. Similarity between the SARS-CoV-2 -related phenotype and the healthy lung tissue males and females 
Analysis of the sex-specific enrichment of the COVID-19-related gene signature in the lung tissue of 
healthy subjects was performed using the GTex library, implemented in the EnrichR utility. Overall, 
47 and 87 samples of lung tissue were tested from females and males, respectively. As shown in 
Figure 4, in the fourth decade of life, the female lung tissues has a more similar phenotype to that 
induced upon SARS-CoV-2 infection than identical tissues from men (p=0.019 by Mann-Whitney U 
test). No significant differences were observed between male and female tissues in other decades of 
age, although a similar trend is observed at the age of 50-59 years (Figure 4) 
 
 
Figure 4. Combined score of the similarity between the SARS-CoV-2-related phenotype and the 
healthy lung tissue 
 
 
4. Discussion 
Even though recent evidence indicate that most cases of COVID-19 have an asymptomatic or 
subclinical course of infection, a significant proportion of patients develop flu-like symptoms of 
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 variable severities that may require hospitalization. In addition, a group of high risk individuals has 
been identified that include older people, individuals affected by other comorbidities, such as 
diabetes and hypertension, and those with a history of smoking, who are susceptible to develop a 
severe course of SARS-CoV-2 infection [18–20]. The percentage of lethality due to COVID-19 infection 
varies greatly between different countries, for example from ~11% in Italy to ~1% in neighboring 
Germany. The reasons for this are not entirely clear although some countries express lethality as case 
fatality rates, others as infection fatality rates; the latter depending on the SARS-CoV-2 testing 
capacity of individual countries. Different lethalities also depend on patient-related factors, including 
comorbidities especially in older individuals. Development and severity of COVID-19 also appears 
to depend on individual propensities for massive release of proinflammatory and immunoactivating 
cytokines including interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, tumor necrosis factor-α (TNF-α) and 
chemokines (CXC-chemokine ligand 10 (CXCL10) and CC-chemokine ligand 2 (CCL2) at the level of 
the infected lung tissues and accumulating immune cells [2,21] developing a reaction known as 
Cytokines Release Syndrome (CRS). This is likely to promote self-sustaining inflammatory processes 
that may contribute to the development of respiratory failure and systemic, possibly lethal, 
manifestations similar to those seen in patients with e.g. meningococcal sepsis: hyperthermia, 
catastrophic multiple organ failure, shock and disseminated intravascular coagulation [22]. It is of 
interest that CRS characterizes secondary haemophagocytic lymphohistiocytosis (sHLH), that is an 
under-recognized, hyperinflammatory syndrome characterized by a fulminant and fatal 
hypercytokinaemia with multiorgan failure. In adults, sHLH is most commonly triggered by viral 
infections and occurs in 3·7–4·3% of sepsis cases [21].  
Predictors of fatality from a recent retrospective, multicenter study of 150 confirmed COVID-19 cases 
in Wuhan, China, included elevated ferritin (mean 1297·6 ng/ml in non-survivors vs 614·0 ng/ml in 
survivors; p<0·001) and IL-6 (p<0·0001), suggesting that mortality might be due to virally driven 
hyperinflammation [2,21]. 
A “cytokine storm” underlying lethal outcomes of COVID-19 is also supported by anecdotical though 
repeated observations that the anti-IL-6 receptor antibody, tocilizumab, appears to beneficially 
influence the course of COVID-19. This has led to the initiation of Phase II and Phase III studies of 
tocilizumab in these patients [23]. Other anti-inflammatory therapeutics, including glucocorticoids, 
JAK inhibitors and choloroquine/hydrocholoroquine, may also improve patients’ prognosis [24]. It 
should be noted, however, that the ability of glucocorticoids to block production of the potentially 
most dangerous cytokines, TNF-α and IL-1𝛽, occurs largely at the genomic level therefore requiring 
several hours for effective manifestation. This hampers the effectiveness of glucocorticoid therapies 
in catastrophic situations where high amounts of these cytokines have already been released to the 
circulation. In contrast, specific anti-cytokine antibodies or receptor antagonists clinical approved on 
other indications would be expected to have an immediate neutralizing effect that might reduce 
mortality. 
 
The identification of the precise pathogenic mechanisms by which SARS-CoV-2 induces organ 
damage are of immediate urgency. Unfortunately, emerging data seem to indicate that other organs 
such as heart, kidney and the central nervous system may also be attacked, albeit in a more silent 
 fashion, by SARS-CoV-2 [25,26]. Indeed, patients may show proteinuria, elevated baseline serum 
creatinine levels and hematuria [25], as well as neurological symptoms, that include headache, 
epilepsy, disturbed consciousness, anosmia and dysgeusia [26]. Some COVID-19 patients also 
develop a thrombogenic diathesis that is characterized by marked elevation of D-dimer and other 
procoagulant parameters diverging from those observed during SARS infections [27]. Thus, 
anticoagulant treatment is associated with decreased mortality in severe COVID-19 patients with 
coagulopathy [28]. Understanding whether or not a cytokine storm also contributes to damage to 
these organs or if other pathogenetic mechanisms operate is clearly needed to develop organ-tailored 
therapeutic approaches.  
 
While waiting for the eventual advent of a vaccine, other drugs used for different indications may be 
repurposed to treat COVID-19 patients, as well. These include a few antiviral options under clinical 
trial, e.g. remdesivir [29], and lopinavir/ritonavir given alone or in combination with interferon- and 
hydroxychloroquine alone or with azitromicin (ClinicalTrials.gov identifier: NCT04332107; 
NCT04339816; NCT04336332; NCT04332094; NCT04335552; NCT04322123). 
 
The use of whole-genome expression data has been extensively used by ourselves and others for the 
identification of novel pathogenic pathways and therapeutic targets in several human pathologies 
including, autoimmune diseases [30–32] and cancer [33,34]. Network analysis allows to extensive 
testing of different biological features [35] and to extrapolate new information that otherwise would 
be lost. Here, we have used computational methods and network analysis to better characterize the 
cellular response to SARS-CoV-2 infection, suggesting the molecular basis for the observed gender 
differences and to predict possible new therapeutic targets. We exploited a publicly available RNA-
seq dataset, GSE147507, generated from primary lung cells upon infection with SARS-CoV-2 thus 
extending analyses of the original data published by Blanco-Melo et al. [8]. We focused on 
comparisons of the transcriptional signature induced by SARS-CoV-2 and SARS-CoV from the 2003 
pandemic and on the molecular mechanisms likely involved in gender differences in COVID-19 
susceptibility. Using an in silico-pharmacology approach, we have also presently predicted potential 
drugs for COVID-19 treatment. Our work differs substantially from the study by Guzzi and 
colleagues [36], as their study explores the SARS-CoV-2/host receptor recognition and makes use of 
predicted functional interactions based on convergent SARS-CoV and Middle East respiratory 
syndrome coronavirus (MERS-CoV) transcriptional profiles generated on established lung cancer 
cells [36]. 
 
Our study revealed that many differentially expressed genes are involved in inflammation and 
response to external organisms, such as S100A7A, CSF3, ICAM2, CCL20, CXCL3, IL6, CSF2, CXCL5, 
IL8, ICAM1, OAS1. These genes are known to promote the recruitment and activation of granulocytes, 
monocytes and macrophages proliferation and infiltration, that, as mentioned before, is one of the 
key features of COVID-19. As expected, the most important transcription factor regulating the 
response to COVID-19 is RELA, which is involved in NF-kB formation and controls both proliferative 
and inflammatory cellular responses [37]. Interestingly, other representative transcription factors in 
 our network are implicated in mechanisms of DNA damage and repairing and chromatin remodeling 
events, such as RAD21, CTCF, SPI1 and GATA2 [38–41].  
 
To better understand the similarities between SARS infection, we also compared the transcriptomic 
profile induced by SARS-CoV-2 infection and SARS infections at different time points. The results 
show that the transcriptomic signature induced by SARS-CoV-2 infection correlates better with the 
latest stages of SARS infection and, accordingly, many biological pathways related to cytokine 
response and host defense mechanisms are shared between COVID-19 24h and SARS 72h and 96h. 
Hence, we propose that the accelerated cellular response to SARS-CoV-2, in comparison to SARS, 
may explain the higher ability of SARS-CoV-2 to spread [2]. 
 
Next, by using an anti-signature analysis approach [42,43], we have predicted possible novel drug 
options for the treatment of SARS-CoV-2 infection. Even if the mechanism of action of most  of the 
predicted target molecules is not yet known, other targeting drugs are anti-inflammatory 
(glucocorticoids) and anti-proliferative drugs, such as Mitogen-activated protein kinase kinase 
(MEK), serine-threonine kinase (AKT), mammalian target of rapamycin (mTOR) and I kappa B 
Kinase (IKK) inhibitors. In agreement with data by Zhou et al. [44], our analysis shows that the mTOR 
inhibitor, sirolimus, may be a candidate drug for use in COVID-19 patients. Moreover, in an in vitro 
study, extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and 
phosphoinositol 3-kinase (PI3K)/AKT/mTOR signaling responses were previously found to be 
modulated in response to the infection with another coronavirus, MERS-CoV [45]. Studies have also 
shown that the mammalian target of rapamycin complex 1 (mTORC1) is a key factor in regulating 
the replication of viruses [45,46], and in patients with H1N1 pneumonia, early treatment with 
corticosteroids and an rapamycin has been associated with improvement in hypoxia, multiple organ 
dysfunction, virus clearance, and shortened time in ventilators [47]. Low-dose inhibitors of mTORC1 
are also beneficial in the elderly by increasing immune function and reducing infections and 
complications [48]. We have also generated in vivo proof-of-concept that sirolimus is effective in 
prevention of HIV replication in a humanized SCID model [49] and have proposed the use of 
rapamycin in HIV infection and its complications [50,51]. Subsequently, our in vivo data have been 
replicated in the same model by Heredia et al., using an ATPase inhibitor of mTOR  [52], and it has 
been further extended by Latinoci et al., in a different mouse model of HIV infection, where they 
showed the synergistic antiretroviral action of rapamycin with standard antiretroviral therapy [53]. 
Recent data have also demonstrated a possible antiretroviral action of rapamycin in HIV-infected 
kidney transplant recipients. It appears therefore that an antiviral mode of action of rapamycin 
coupled with its immunomodulatory potential that may dampen excessive production of 
proinflammatory cytokines would warrant clinical studies with this drug in selected patients with 
COVID-19 [54]. 
 
Despite this, we have to acknowledge the limitations of the present study. First, the differentially 
expressed genes, that we have prioritized in our study, have been obtained from the analysis of an in 
vitro model of SARS-CoV-2 infection, hence the data may be incomplete, and functional associations 
occurring in patients may be missing. Studies integrating lung-specific gene expression profiles with 
 the SARS-CoV-2 infection-related gene signature may help to better identify potential repurposable 
drugs. Also, although some of our findings have been confirmed by various literature data, most of 
the predicted repurposable drugs need to be validated and, for several of them, preclinical studies 
are warranted to evaluate in vivo efficiency and side effects before clinical trials. Indeed, our 
approach cannot identify dose–response and dose–toxicity effects for the candidate drugs. 
Furthermore, drug combinations targeting multiple pathogenic pathways can be envisioned, as it has 
been the case for standard antiretroviral therapy with rapamycin in a mouse model of HIV [53] . 
Despite these limitations, our study can minimize the translational gap between preclinical data and 
clinical application, which appears an issue of paramount relevance in view of the unprecedent social 
and epidemiological emergence provoked from the rapid escalation of the SARS-CoV-2 outbreak. 
 
To decipher the reasons for the gender differences in COVID-19 susceptibility [2], we have compared 
the transcriptomic profile of lung tissue from healthy women and men with the transcriptomic 
induced by COVID-19. At ages between 40 and 60 years, the transcriptomic feature of the female lung 
tissue was more similar to those induced by COVID-19 than in male tissue. A lower threshold of 
acute response to SARS-CoV-2 infection in men may at least partly explaine the reduced incidence of 
COVID-19 in women. This hypothesis will need to be weighed and validated on the ground of 
appropriate epidemiological data that will allow to ascerain whether the apparent protection from 
COVID-19 infection in famales is specifically observed in the above-indicated range of age. If so, next 
question will be whether this ”physiological” observation may be translated into therapeutic 
opportunity by dismantling those potential factors that might have contributed to the induction of 
this ”COVID-19-resistant lung phenotype” in women of these ages. Clearly, female-specific hormonal 
factors for example occurring just before or during the menopausal period can be implicated. 
In this regard, it is notable that among the SARS-CoV-2-induced genes encoding the neutrophil 
chemotactic factor CXCL1 and the predominantly dendritic cell chemotactic factor CCL20 are 
regulated by androgen receptor AR (androgen receptor), whereas C3 and EDN1 are regulated by 
ESR1 (estrogen receptor 1). AR plays a role in innate and adaptive immune regulations [55,56], 
especially in the recruitment of neutrophils and macrophages, that are been proven to be strongly 
associated with COVID-19 in lung tissue [24]. Both CXCL1 and CCL20 emerged in the top 50 ranking 
nodes in our network ordered by degree, and both are modulated even during SARS infection [57,58]. 
This suggests their involvement in different coronavirus infections and, in addition, a different role 
in female and male responses to these infections.  
It is noteworthy that ER is involved as regulators of immune responses by enhancing interferon 
production and anti-viral response [59], and that selective oestrogen receptor modulators have been 
proposed as potential drugs to treat coronavirus infection [44]. Toremifene, for example, potentially 
affects several key host proteins associated with coronavirus: RPL19, HNRNPA1, NPM1, EIF3I, 
EIF3F, and EIF3E. Taken together, these convergent observations point to mechanisms that may 
explain the lower female incidence and/or lethality of COVID-19 offering candidate therapeutic 
options in patients with SARS-CoV-2 infection. 
5. Conclusions 
 COVID-19 is a severe infection currently spreading as a pandemic. Here, we have investigated the 
transcriptomic profile of primary human lung cells upon infection with SARS-CoV-2, characterizing 
the most activated intracellular pathways and in order to provide a molecular explanation for the 
gender differences in the clinical manifestations. Finally, we have identified new potential drugs for 
COVID-19 therapies. We found that targeting the mTOR pathway could be a promising therapeutic 
avenue to fight COVID-19, improving symptomatology and reducing mortality rates.  
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